tbuckley/cabot-search huggingface dataset:
Phase I clinical results of an APC-targeted hCGβ vaccine (CDX-1307) with TLR agonists
Authors: M. Morse, R. Chapman, J. Powderly, T. Keler, L. He, V. Ramakrishna, L. Vitale, T. Clay, J. Green, T. Davis
Journal: Journal of Clinical Oncology (2009)

3006 Background: Effective immunization requires efficient antigen delivery to antigen presenting cells (APCs). Antigens attached to the human antibody B11, targeting mannose receptors on APCs, have been shown to be processed and presented efficiently, and generate robust immune responses when combined with toll-like receptor (TLR) agonists. The CDX-1307 vaccine is composed of B11 fused with hCGβ, a tumor antigen correlated with advanced stage of disease and poor prognosis in a number of common epithelial cancers, but reported at variable rates of expression. Methods: Two phase I studies investigate intradermal (id) vs. systemic (iv) administration of CDX-1307. Patients with advanced epithelial cancers known to frequently express hCGβ receive 4 biweekly vaccinations of CDX-1307, alone or in combination with immunostimulants including GM-CSF (GM), the TLR3 agonist Poly-ICLC, and the TLR7/8 agonist resiquimod. Results: Dose-escalation is complete. In the id study, 37 patients received CDX-1307 at doses of 0.3, 1.0, and 2.5 mg, then 2.5 mg + GM, 2.5 mg + GM + Poly-ICLC, and 2.5 mg + GM + resiquimod. 2.5 mg + GM + Poly-ICLC + resiquimod is planned. In the iv study, 24 patients were treated at 1, 3, 10, and 30 mg, as well as 10 mg + GM and 30 mg + GM. 30 mg + GM + Poly-ICLC is enrolling. Treatment-related toxicities were generally mild to moderate with no dose-limiting toxicities, most frequently injection site reactions and fatigue in the id study, and fatigue, myalgia, and flu-like illness in the iv study. Humoral responses to hCGβ were increased in 56% of the analyzed patients receiving adjuvants. Serum hCGβ was frequently elevated at study entry or during treatment (males = 88%, females = 53%, pancreatic = 89%, colorectal = 78%, breast = 47%). hCGβ decreases were seen in some patients with immune responses. To date, a significant mixed response was seen in one patient with pancreatic cancer (id), while stable disease has been seen in 4 patients (2 with breast cancer = 25, 27 weeks and 2 with colorectal cancer = 9+ weeks). Conclusions: CDX-1307 is well tolerated and results in immune responses that are enhanced by immunostimulants. Elevated hCGβ was detected at a higher than expected frequency in these tumors. [Table: see text]
Kinetics of Nitrosation of the Amino Acids Proline, Hydroxyproline, and Sarcosine23
Authors: S. S. Mirvish, J. Sams, T. Y. Fan, S. R. Tannenbaum
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Kinetics of Nitrosation of the Amino Acids Proline, Hydroxyproline, and Sarcosine Get access S. S. Mirvish, S. S. Mirvish 4Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Neb. 68105 Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Sams, J. Sams 4Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha, Neb. 68105 Search for other works by this author on: Oxford Academic PubMed Google Scholar T. Y. Fan, T. Y. Fan 5Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Mass. 02139 Search for other works by this author on: Oxford Academic PubMed Google Scholar S. R. Tannenbaum S. R. Tannenbaum 5Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Mass. 02139 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 6, December 1973, Pages 1833–1839, https://doi.org/10.1093/jnci/51.6.1833 Published: 01 December 1973 Article history Received: 12 March 1973 Accepted: 30 July 1973 Published: 01 December 1973
The 1.35-kb and 7.5-kb Duffy mRNA Isoforms Are Differently Regulated in Various Regions of Brain, Differ by the Length of Their 5′ Untranslated Sequence, but Encode the Same Polypeptide
Authors: Caroline Le Van Kim, Christophe Tournamille, Yolande Kroviarski, Jean Pierre Cartron, Yves Colin
Journal: Blood (1997)
CD26 Inhibition Can Aid the Homing of Cytokine Activated Mobilized Peripheral Blood (MPB )CD34+ Cells to the Bone Marrow (BM) but a Ligand Dependent Attachment Defect Prevents Their Long Term Retention and Subsequent Engraftment
Authors: Konstantina Kallinikou, Fernando Anjos-Afonso, Michael P Blundell, Stuart J Ings, Deepika Kassen, Adrian J Thrasher, David C Linch, Dominique Bonnet, Kwee Yong
Journal: Blood (2011)
Medicine's Wild West — Unlicensed Stem-Cell Clinics in the United States
Authors: Hermes Taylor-Weiner, Joshua Graff Zivin
Journal: New England Journal of Medicine (2015)

Interview with Dr. Hermes Taylor-Weiner on the regulation of stem-cell clinics offering unproven therapies. (05:53)Download Many stem-cell clinics have capitalized on public confusion by selling treatments that are not approved by the FDA, supported by clinical studies, or covered by insurers. Given ambiguous FDA guidelines, these clinics have in effect been operating without regulation.
Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)
Authors: M. De Santis, P.J. Wiechno, J. Bellmunt, C. Lucas, W.-C. Su, L. Albiges, C.-C. Lin, E. Senkus-Konefka, A. Flechon, L. Mourey, A. Necchi, W.C. Loidl, M.M. Retz, N. Vaissière, S. Culine
Journal: Annals of Oncology (2015)

There is no standard first-line chemotherapy for advanced urothelial carcinoma (aUC) in cisplatin-ineligible (cisplatin-unfit) patients. The study assessed the efficacy and tolerability profile of two vinflunine-based cytotoxic regimens in this setting.Patients with aUC a creatinine clearance (CrCl) of <60 but ≥30 ml/min, performance status 0 or 1 and no prior chemotherapy for advanced disease were randomized (1 : 1). They received vinflunine 250 or 280 mg/m(2) (based on baseline CrCl) on day 1, plus either gemcitabine [750 mg/m(2) escalated to 1000 mg/m(2) in cycle 2 if no toxicity grade (G) ≥2 on days 1 and 8 (VG) or plus carboplatin area under the curve 4.5 day 1 (VC) every 21 days]. To detect a 22% improvement in each arm compared with H0 (41%) in the primary end point, disease control rate (DCR = complete response + partial response + stable disease), 31 assessable patients per arm were required (α = 5%, β = 20%).Sixty-nine patients were enrolled (34 VG, 35 VC). Less G3/4 haematological adverse events (AEs) were reported with VG: neutropaenia was seen in 38% (versus 68% with VC) and febrile neutropaenia in 3% (versus 14% with VC) of patients. No major differences were observed for non-haematological AEs. DCR was 77% in both groups; overall response rate (ORR) was 44.1% versus 28.6%, with a median progression-free survival of 5.9 versus 6.1 months and median OS of 14.0 versus 12.8 months with VG and VC, respectively.Both vinflunine-based doublets offer a similar DCR, ORR and OS. The better haematological tolerance favours the VG combination, which warrants further study. CLINICALTRIALS.GOV PROTOCOL IDENTIFIER: NCT 01599013.
Clinicopathologic Characteristics Of Secondary Malignancies In Survivors Of Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Hematologic Malignancies
Authors: Chakra P Chaulagain, Esha Kaul, Monika Pilichowska, Andreas K. Klein, Kellie Sprague, Kenneth B. Miller
Journal: Blood (2013)
<i>SUV39H2</i> polymorphisms and the risk of lung cancer
Authors: B. Hwangbo, I.-J. Kim, H. J. Kee, H. S. Kim, C. S. Park, J. M. Kim, C. G. Park, Y. K. Jang, J.-G. Park, J. S. Lee
Journal: Journal of Clinical Oncology (2005)

9582 Background: Histone methylation is an important step for forming heterochromatin and the regulation of gene functions. SUV39H methyltrasferase, which targets histone H3 lysine 9, has two types of genes in human, SUV39H1 and SUV39H2. SUV39H1 was found to interact with Rb protein and Suv39h1/h2 double knockout mice had an increased risk of lymphoma. We investigated the relation of SUV39H2 polymorphisms and lung cancer. Methods: Among 8 novel SNPs identified on the SUV39H2 gene through direct PCR sequence, we examined 6004G/C (3’ UTR) polymorphism on DNA samples from 348 (M/F= 237/111) lung cancer (LC) cases and 423 (M/F=242/181) controls without cancer (NC) using an automatic direct sequencing and a real-time PCR (TaqMan assay). Results: The minor allele frequency was 9.8% and 7.1% for LC and NC, respectively. There was no effect of gender or smoking status on genotype distribution. The distribution of non-wild genotype (GC + CC) by smoking status and age group (<55 vs. ≥55 years) is shown in the table. Overall, non-wild genotype was associated with a modest increase in the risk of lung cancer compared to GG genotype for ever-smokers (OR=1.73, 95% CI=0.99–3.05) but not for never-smokers (OR=1.02, 95% CI=0.54–1.93). This SUV39H2 genotype-associated increase in the risk of lung cancer was more pronounced in the old age group ever-smokers (OR=2.47, 95% CI=1.06–5.75). Conclusion: SUV39H2 6004G/C (3’ UTR) polymorphism was associated with an increased risk of lung cancer in smokers, which became apparent in the old age group. More studies are needed to elaborate the role of SUV39H2 in carcinogenesis and gene-environment interaction. (Supported in part by NCC grant 0210040) No significant financial relationships to disclose.
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Authors: Anna F. Farago, Long P. Le, Zongli Zheng, Alona Muzikansky, Alexander Drilon, Manish Patel, Todd M. Bauer, Stephen V. Liu, Sai-Hong I. Ou, David Jackman, Daniel B. Costa, Pratik S. Multani, Gary G. Li, Zachary Hornby, Edna Chow-Maneval, David Luo, Jonathan E. Lim, Anthony J. Iafrate, Alice T. Shaw
Journal: Journal of Thoracic Oncology (2015)
Differing Perspectives on Breast Cancer Chemoprevention
Authors: Jack Cuzick, Larry Wickerham, Trevor Powles
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 115: The Changes in Cardioelectrical Activity of Rat With Myocardial Infarction Receiving Sarcoplasmic Reticulum Ca <sup>2+</sup> -ATPase Gene Modified Bone Marrow Stem Cell Transplantation by Microelectrode Array Technology
Authors: Fan Ping, Hou Yuemei, Wang Lingpeng, Wang Huan, Xu Xiaoxia, Yang Xi, Zhang Guangwei, Wang Hongli
Journal: Circulation Research (2012)

0bjective Comparison of bone marrow stem cells (BMSCs) transplantation and sarcoplasmic reticulum Ca 2+ -ATPase (SERCA2a) gene modified BMSCs transplantation for therapy effects after acute myocardial infarction(AMI), as well as for assessment cardiac electrical activity by microelectrode array (MEA) technology. Methods Rats with myocardial infarction ( n =24)and divided into 3 groups randomly: Sham group ( n =8), BMSCs group( n =8) and SERCA2a gene modified BMSCs transplantation group (BMSCs+rAd.SERCA2a group, n =8). After 14 days, cardiac function was evaluated by echocardiography and heart electrical activity was evaluated by electrocardiogram and MEA technology. Results (1)The transduction ration of rAd.SERCa2a to BMSCs were 80% to 90%. (2)Compared to sham group, BMSCs group and BMSCs+rAd.SERCA2a group could significantly improve cardiac function on 14 days after therapy ( n =6, P &lt;0.05).(3)QT duration of BMSCs+rAd.SERCA2a group was significantly shorter than in the sham group(80.30 ms±6.53 ms versus 105.31 ms±21.89 ms),the mean value was significantly decreased 23.8%( n =7, P &lt;0.05). Ventricular premature beats were also recorded in rats from sham group.(4)MEA results suggested that isolated heart beats were significantly slowed and ventricular arrhythmias and atrioventrocular block were recorded in sham group. The maximum field potential and field potential duration of infarcted myocardium area in BMSCs group and BMSCs+rAd.SERCA2a group were significantly longer than those in sham group(the maximum field potential: 0.51 mV±0.15 mV, 0.55 mV±0.16 mV, 0.23 mV±0.1mV; field potential duration: 104.5 ms±25.43 ms, 107.67 ms ±24.01 ms, 63 ms± 20.34 ms; n =6, P &lt;0.05).(5)The conduction time was the shortest in BMSCs+rAd.SERCA2a group, the cardiac electrical conduction could keep consistency and improve in myocardial infarction tissue. Conclusions In short time, BMSCs and SERCA2a gene modified BMSCs transplantation could obviously enhance cardiac function. BMSCs+rAd.SERCA2a group could effectively improve electrical conduction of infarcted myocardium and block the occurrence of arrhythmia after myocardial infarction.
Tumors in Rhesus Monkeys Inoculated at Birth With Homologous Cells Converted &lt;italic&gt;In Vitro&lt;/italic&gt; by Rous Sarcoma Virus, Schmidt-Ruppin Strain
Authors: G. F. Rabotti, J. C. Landon, T. W. Pry, L. Beadle, J. Doll, D. P. Fabrizio, A. J. Dalton
Journal: JNCI Journal of the National Cancer Institute (1967)

In vitro infection of cells from dura leptomeninges and cerebrum of rhesus (Macaca mulatto) monkey with Rous sarcoma virus, Schmidt-Ruppin strain (SR-RSV), led to discrete foci of morphologically converted cells. These converted cells maintained their morphology on serial transfers in vitro. Inoculation of SR-RSV-converted leptomeningeal cells by different routes into 3 newborn rhesus monkeys resulted in malignant, infiltrating, metastasizing sarcomas in these hosts. No tumors were induced by inoculation of normal leptomeningeal cells into a newborn rhesus. No infectious virus was recovered from the rhesus SR-RSV-converted cells. Whole cell transplantation of converted cells into chicken wing webs induced typical virogenic Rous sarcomas. The converted cells contained the RSV group-specific antigen, as shown by complement fixation. No particles with the morphology of viruses of the avian leukosis complex could be shown by electron microscopy after examination of two cultures of converted cells. Inoculation of cell-free RSV of the Bryan, SR, and CT559 strains, at various high doses, induced regressing fibromas in 40 newborn rhesus, 3 newborn cynomolgus, 2 newborn galagos, and 2 juvenile green monkeys. The failure of newborn monkeys to develop a malignant tumor when inoculated with RSV apparently is not genetically determined in the target cell, since in vitro infection produced malignancy in cells from rhesus monkeys infected by SR-RSV.
Preservation of erectile function after permanent radioactive seed implantation for treatment of prostate cancer
Authors: R. D. Steinmetz, W. L. Barrett
Journal: Journal of Clinical Oncology (2007)

15596 Purpose: Assess erectile function before and after prostate brachytherapy. Materials and Methods: A total 241 patients were treated with permanent I-125 prostate brachytherapy for T1 and T2 adenocarcinoma of the prostate. A retrospective chart review was undertaken to assess erectile function before and after treatment using the scoring system of, 1- complete inability to have erections, 2 - can sometimes have erections sufficient for intercourse with or without medication, and 3 - has normal erectile function. Pretreatment testosterone levels were reviewed for correlation with pretreatment erectile function. Results: The median age was 68. At presentation, the median age of patients with erectile scores of 1, 2 and 3 was 70, 67 and 67 respectively. The median time of follow-up was 48 months. Pretreatment erectile function assessment revealed scores of 1 in 28%, 2 in 27% and 3 in 45% of patients. Median pretreatment testosterone levels were 296 ng/dl in the patients with pretreatment score of 1 compared to 360 ng/dl in patients with a score of 2 and 370 ng/dl in patients with a score of 3. The normal testosterone range for this age group is 165 ng/dl to 830 ng/dl. After 12 months erectile function assessment revealed scores of 1 in 29%, 2 in 42% and 3 in 29% of patients. After 24 months erectile function assessment revealed scores of 1 in 30%, 2 in 41% and 3 in 29% of patients. After 36 months erectile function assessment revealed scores of 1 in 32%, 2 in 45% and 3 in 23% of patients. After 48 months erectile function assessment revealed scores of 1 in 39%, 2 in 36% and 3 in 25% of patients. After 48 months, the median age of patients with erectile scores of 1, 2 and 3 was 75, 69 and 66 respectively. After 60 months erectile function assessment revealed scores of 1 in 32%, 2 in 47% and 3 in 21% of patients. After 72 months erectile function assessment revealed scores of 1 in 24%, 2 in 52% and 3 in 24% of patients. 49% of patients were given sildenafil, vardenafil, or tadalafil to improve erectile function. Conclusion: The rate of potency preservation in this cohort declined in an expected manner after permanent brachytherapy for prostate cancer. No significant financial relationships to disclose.
Tinzaparin prophylaxis in brain tumor patients
Authors: C. W. Bohlin, D. A. Reardon, A. Desjardins, J. A. Quinn, J. N. Rich, D. A. Bota, K. Goli, H. S. Friedman, J. J. Vredenburgh
Journal: Journal of Clinical Oncology (2007)

12506 Background: Thromboembolic disease is the second leading cause of death in brain tumor patients. Various studies have documented a 20–40% risk of deep vein thrombosis and / or pulmonary embolus in brain tumor patients. When used as prophylaxis, Tinzaparin, a low molecular weight heparin with factor Xa activity, has a low complication rate and low incidence of bleeding complications. With the anticipated benefit exceeding any risk, prophylaxis with Tinzaparin may be safe and effective. Methods: A phase II trial of prophylactic tinzaparin for newly diagnosed brain tumor patients has completed accrual at 40 patients. A fixed daily dose of 4500 IU subcutaneous tinzaparin was given beginning a minimum of 48 hours post-operatively and a maximum of 4 weeks post-operatively. Patients consented to take tinzaparin daily for 12 months. Weekly blood counts were monitored during chemotherapy cycles. Tinzaparin was held if platelet count was &lt;50,000 and resumed once the platelets were &gt;100,000. Tinzaparin was discontinued in patients who began treatment with avastin. Results: Of 40 patients, 7 remain on treatment. Patients have taken tinzaparin for 4–52 weeks with a median of 21 weeks. One of the patients developed a grade 3 CNS hemorrhage and one had a grade 1 CNS hemorrhage, necessitating cessation of the tinzaparin, there have been no grade 4 or 5 CNS hemorrhages or treatment associated mortality. No patients developed = grade 2 systemic hemorrhages. One patient developed a deep venous thrombosis while taking tinzaparin, and three patients developed thromboembolic complications while off tinzaparin secondary to thrombocytopenia. One patient was taken off study for increased liver function tests, possibly secondary to tinzaparin. Conclusions: Thus far, daily prophylactic tinzaparin has proven safe and effective in decreasing the incidence of thromboembolic disease in brain tumor patients. We plan a phase III study upon the safe completion of the last 7 patients on this phase II study. No significant financial relationships to disclose.
Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
Authors: Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Journal: Clinical and Molecular Hepatology (2015)

The previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions. A new era of direct-acting antivirals is now dawning in Korea. Early experience of applying sofosbuvir-based therapy to CHC patients in Korea is reported herein.Data on efficacy and safety were collected for CHC patients treated with a combination of sofosbuvir plus ribavirin or sofosbuvir/ledipasvir with or without ribavirin.This retrospective study included 25 consecutive patients who received sofosbuvir-based therapy (19 with genotype 1b and 6 with genotype 2) at Seoul National University Hospital from May 2014 to April 2015. A virologic response was achieved at week 4 by 85.7% and 80% of the patients with genotypes 1b and 2, respectively. The HCV-RNA level decreased more slowly in IFN-experienced than in treatment-naïve patients with genotype 1b. However, the sustained virologic response at week 12 (SVR12) rate did not differ among these patients, and was as high as 100%. The presence of cirrhosis significantly increased the risk of a virologic response failure at week 4 (OR, 11.0; P=0.011) among patients with HCV genotype 1b. Only five patients (20%) experienced minor adverse events, including grade 1 fatigue and headache. The hemoglobin level decreased slightly after sofosbuvir-based therapy, but there was no case of premature discontinuation of this therapy.In a real clinical practice, sofosbuvir-based therapy for CHC patients in Korea achieved optimal antiviral efficacy with insignificant adverse events. Long-term follow-up data are warranted to ensure the sustained antiviral efficacy and long-term safety of sofosbuvir-based IFN-free therapy.